Treatment-Resistant Hypertension Market is Anticipated to Showcase Immense Growth by 2032, Predicts DelveInsight | Key Companies - Idorsia, Janssen Biotech, Quantum Genomics, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma
09. April 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, April 09, 2024 (GLOBE NEWSWIRE) -- Treatment-Resistant Hypertension Market is Anticipated to Showcase Immense Growth by 2032, Predicts DelveInsight | Key Companies - Idorsia, Janssen...
Treatment-Resistant Depression Market to Observe Stunning Growth by 2032, Assesses DelveInsight | Key Companies to Watch Out - Navitor, Supernus, Novartis, Relmada, Beckley Psytech, COMPASS, Axsome, Celon Pharma
19. Oktober 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Treatment-Resistant Depression Market to Observe Stunning Growth by 2032, Assesses DelveInsight | Key Companies to Watch Out - Navitor, Supernus,...
PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health
01. Mai 2023 18:52 ET
|
PharmAla Biotech
CORTEXA TO BE THE LEADING SUPPLIER OF MDMA AND PSILOCYBIN IN AUSTRALIA VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is...
Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change
03. Februar 2023 00:01 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) applauds the Australian Therapeutic Goods Administration (TGA) in allowing for...
Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression
09. August 2021 07:00 ET
|
Axsome Therapeutics, Inc.
AXS-05 significantly delayed the time to relapse of depression compared to placebo (p=0.002, primary endpoint) AXS-05 significantly prevented relapse of depression over at least 6 months compared to...
Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression
02. Dezember 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Rapid and substantial improvement in depressive symptoms achieved by 44% of patients at 2 weeks, 67% at 6 weeks (MADRS response), and sustained with long-term treatment Rapid and substantial...
Axsome Therapeutics Presents Data from GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder at the 2020 American Society for Clinical Psychopharmacology Annual Meeting
29. Mai 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 29, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
08. Mai 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further deepen innovative...
Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications
30. März 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Achieves key secondary endpoints demonstrating rapid and statistically significant improvements in depressive symptoms on MADRS versus active comparator at Weeks 1, 2, and overall (key secondary...
Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
24. Juni 2019 07:00 ET
|
Axsome Therapeutics, Inc.
First patient enrolled in placebo-controlled GEMINI study Topline results anticipated in 2H 2019 NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...